BHI Weekly Newsletter Archives Archives - Page 33 of 66

Feb 28 2019

Love0

343rd Edition – February 26, 2019

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

February 26, 2019

FOUNDING MEMBER OF

2/28 SBIR & Non-Dilutive Funding Workshop

University of Maryland Institute for Bioscience & Biotechnology Research, 9600 Gudelsky Drive, Rockville, MD 20850

Register NOW: https://tinyurl.com/BHISBIR2019

8:00 a.m. – Networking and Registration
8:30 a.m. – Welcome
8:35 a.m. – SBIR Funding Opportunities at the National Institutes of Health
- National Heart, Lung, and Blood Institute
- National Institute on Aging
- National Institute on Drug Abuse
- National Cancer Institute
9:45 a.m. – Partnership Opportunities with NCI Frederick National Lab
10:00 a.m. – BREAK
10:20 a.m. – SBIR Funding Opportunities with the National Science Foundation
11:00 a.m. – BREAK
11:15 a.m. – SBIR Funding Opportunities with USAMRC
11:45 a.m. – Lunch
12:45 p.m. – (1:1 Room Set)
1:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
1:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously)
2:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
2:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously))
3:00 p.m. – 1:1 Meetings* (NIH only)
4:00 p.m. – Adjourn

Pre-Registration REQUIRED: RSVP by noon, February 26 at https://tinyurl.com/BHISBIR2019No charge for entrepreneurs to attend • NOTE: Most 1:1 meeting(s) timeslots now are booked but when you list your agency interests in the RSVP we will be certain to let them know to follow up with you with more information.

FOURTH ANNUAL CRAB TRAP COMPETITION

YOU THOUGHT SHARK TANK WAS TOUGH?

NOW ACCEPTING APPLICATIONS at

https://form.jotform.com/90276838255163

Submit your application for a chance to be named the Startup with the Most Commercial Potential at the BioHealth Capital Region Forum, win $10,000 and more!

APPLICATION DEADLINE: March 8, 2019

FINALISTS ANNOUNCED: March 21, 2019

PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019PRESENT AT THE BIOHEALTH CAPITAL REGION FORUM APRIL 9, 2019

Finalists will have a chance to win the grand prize by presenting in front of a panel of prominent industry funding experts and executives.

Distinguished Judges:

Moderator – Rich Bendis, President and CEO, BioHealth Innovation

2019 Judges

John Rubin, Executive Director, JP Morgan Private Bank
Charles J. Andres, Intellectual Property Associate, Wilson Sonsini Goodrich & Rosati (WSGR)
Raghav Bhargava, Associate, New Enterprise Associates (NEA)
Ethel Rubin, NIH Entrepreneur in Residence
Shaun Grady, Vice-President Business Development Operations, AstraZeneca

PRIZES

Grand Prize provided by WSGR $10,000

Visibility in front of hundreds of attendees and prominent industry and venture capital judges

CRITERIA

Product, Technical Feasibility, Marketing/Strategy, Leadership Team, Financial/Projection

SAVE THE DATE – 2019 BioHealth Capital Region Forum

April 8 + 9, 2019

One MedImmune Way, Gaithersburg, MD 20878

This invitation-only event is free for executive level biotech leaders and is presented by BioHealth Innovation, VirginiaBio, Maryland Tech Council, University System of Maryland, Children’s National Health Network, HemoShear, GSK, BeneVir, Quality Biological, Johns Hopkins University and AstraZeneca. Maryland, Virginia, and Washington, DC set the bar high for biotech innovation. So please join us for our Annual BioHealth Capital Region Forum that will highlight the accomplishments of today and chart our successes of tomorrow.

Register at bhcrf2019.eventbrite.com

For more information about our speakers and event schedule, please visit www.bhcrforum.com.

Danaher acquires GE Biopharma for $21.4B – Washington Business Journal

The deal is expected to close in the fourth quarter of this year.

BioHealth Innovation Entrepreneur-in-Residence Feedback – Feb. 27th

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Sign up by noon 3/26 to schedule your feedback session with BHI Entrepreneurs-in-Residence, who have industry experience in therapeutics, Dx, medtech and more, next Wednesday, February 27th. (Future sessions scheduled for 3/20 and 5/22.) Pre-registration is required; sign up here (“EIR resource” at BHI). For questions/more information, contact BHI.

EXCLUSIVE: Amazon Real Estate Head Holly Sullivan Has No Regrets About The HQ2 Search

Amazon changed the rules of economic development when it announced a 50,000-job HQ2 sweepstakes in 2017. While most searches for large facilities happen behind closed doors, the Seattle tech giant kicked off an unprecedented, high-stakes, public battle for its next corporate home.

Maryland still outpacing California among best science, tech environments – Baltimore Business Journal

Maryland has the most computer and data scientists in the U.S., and the second-highest concentrations of engineers and life scientists.

RoosterBio Announces Plans to Expand Facility in Frederick, MD

RoosterBio, Inc, a privately held regenerative medicine manufacturing platform technology company announced plans today to expand the company’s footprint in Frederick, MD after a year of rapid growth.

Qiagen Gets Access to the Largest Genetic Database on Antibiotic Resistance

Under a new licensing deal, Qiagen will gain access to a big genetics database from Vienna-based Ares Genetics, which could help tackle the global health crisis of antibiotic resistance.

Microsoft, global health organizations launch 3 tech programs to catch rare diseases in children

Microsoft outlined how emerging technologies can support diagnosis of rare diseases among children in a report released Feb. 20.

Rare diseases affect almost 350 million people globally, and they can take an average of five years to diagnose, according to the report.

Antidote Therapeutics teams up with National Cancer Institute, seeks funding for nicotine-blocking drug candidate – Washington Business Journal

Matt Kalnik wants to make smoking less addictive.

His clinical-stage company, Gaithersburg-based Antidote Therapeutics Inc., is developing a drug that would diminish the effects of nicotine in the body — to both treat diseases worsened by nicotine and help smokers quit. The businesses is looking to raise between $5 million and $10 million to run over the next two years and get its lead candidate to clinical trials.

Maryland Momentum Fund accepting applications | Office of Technology Commercialization

The Maryland Momentum Fund is a newly-created mechanism for investing in promising early stage companies associated with the University System of Maryland (USM). Maryland-based companies that are seeking equity financing or debt financing that is convertible into equity may apply. The funding provided by the Fund will normally be in the range of $150K-$250K, with a ceiling of $500K. Recipients of this funding must obtain a matching investment (1:1) within six months, in either direction, from the date of commitment by the Fund.

TEDCO Creates Task Force to Support Women Entrepreneurs in Maryland

The Maryland Technology Development Corporation (TEDCO) announced today the formation of the Task Force for Women Entrepreneurs. The task force will be dedicated to the recruitment, funding, and operational support of women-owned and-led startups in Maryland.

University of Maryland Greenebaum Comprehensive Cancer Center Now Among Select Institutions Certified to Administer CAR T-cell Therapy for Lymphoma | UM Greenebaum Comprehensive Cancer Center

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) is now certified to offer a groundbreaking treatment for non-Hodgkin lymphoma, in which a patient’s own immune cells are genetically engineered to recognize and attack the cancer.

Top 10 Immuno-Oncology Startups – GEN – Genetic Engineering and Biotechnology News

GlaxoSmithKline (GSK)’s recently announced $4.2 billion partnership to co-develop and co-commercialize Merck KGaA, Darmstadt’s cancer immunotherapy candidate M7824 was a reminder of just how much biopharma giants are willing to invest in a therapeutic area that has generated sometimes-dazzling results.

Kauffman Indicators of Entrepreneurship

The Kauffman Indicators of Entrepreneurship offers in-depth measures, reports, and accompanying interactive data visualizations that present entrepreneurial trends in the United States.

Like the rest of biopharma investors, corporate VCs love oncology | Evaluate

Novartis scatters its VC seeds widely by leading rounds across a variety of therapy areas, although oncology still represents a big share of its funding activity.

If We Don’t Develop Best Practices Ourselves, the Government Will

To spare you all a power point presentation, I thought I’d share some thoughts today about how and why our tech transfer system was created and the importance of practitioners continually developing best practices to maintain it.

Woody Allen said that half of life is showing up. Perhaps the other half is working with people who give you the opportunity to show what you can do.

MPM Capital raises $400M in seventh venture fund – MedCity News

A life sciences-focused venture capital firm based near Boston has raised more than one-third of a billion dollars to invest in early-stage companies.

Why Food Could Be the Best Medicine of All – Time

When Tom Shicowich’s toe started feeling numb in 2010, he brushed it off as a temporary ache. At the time, he didn’t have health insurance, so he put off going to the doctor. The toe became infected, and he got so sick that he stayed in bed for two days with what he assumed was the flu. When he finally saw a doctor, the physician immediately sent Shicowich to the emergency room. Several days later, surgeons amputated his toe, and he ended up spending a month in the hospital to recover.

Feb 28 2019

Love0

342nd Edition – February 20, 2019

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

February 20, 2019

FOUNDING MEMBER OF

Charles J. Andres, Associate, Intellectual Property with Wilson Sonsini, Goodrich & Rosati (WSGR), joins Rich Bendis for BioTalk to discuss his career, the opportunities/challenges in this industry, and WSGR’s role in the BioHealth Capital

Charles Andres, Ph.D., RAC, is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati. He focuses on patent prosecution, strategic patent counseling, IP due diligence, drug and medical device FDA regulatory counseling, invalidity and non-infringement opinions, life-cycle management, Supreme Court and Federal Circuit amicus briefs, and related business matters.Charles Andres, Ph.D., RAC, is an associate in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati. He focuses on patent prosecution, strategic patent counseling, IP due diligence, drug and medical device FDA regulatory counseling, invalidity and non-infringement opinions, life-cycle management, Supreme Court and Federal Circuit amicus briefs, and related business matters.

Charlie has significant experience drafting patent applications, prosecuting patent applications in the U.S. and abroad, and evaluating the claims of issued patents. He has won cases before the Board of Patent Appeals and Interferences by brief and on oral argument. Patents Charlie has obtained have been listed in the Orange Book and asserted against a generic pharmaceutical manufacturer, and he has drafted and filed multiple applications for patent term extension. Companies he has obtained patents for have been sold for a cumulative total of approximately $4 billion.

Listen now on iTunes , Google Play , and TuneIn.

FOURTH ANNUAL CRAB TRAP COMPETITION

NOW ACCEPTING APPLICATIONS at

https://form.jotform.com/90276838255163

Submit your application by March 1st for a chance to be named

‘the company with the most commercial potential’

at the BioHealth Capital Region Forum

Deadline for entries is March 1, 2019

Finalists will be announced March 21, 2019

Present at BioHealth Capital Region Forum April 9, 2019.

Finalists will have a chance to win the grand prize by presenting in front of a panel of world-class judges.

PRIZES

Grand Prize provided by WSGR $10,000

Visibility in front of hundreds of industry leaders and prominent industry funding experts and executives.

CRITERIA

Product, Technical Feasibility, Marketing/Strategy, Leadership Team, Financial/Projection

SAVE THE DATE – 2019 BioHealth Capital Region Forum

April 8 + 9, 2019

One MedImmune Way, Gaithersburg, MD 20878

For more information about our speakers and event schedule, please visit www.bhcrforum.com.

AstraZeneca retires MedImmune brand – Washington Business Journal

But not everything is expected to change at the Gaithersburg campus.

AURP’s Brian Darmody looks to make College Park office a hub for research parks – Technical.ly Baltimore

Among the organizations taking glass-enclosed office space in the recently opened WeWork at University of Maryland College Park is an organization looking to promote research parks that cluster minds in science and business.

Are the big corporate venture arms retreating? – Evaluate

At the beginning of this decade, when the fallout of the financial crash was still being felt and traditional venture firms were struggling to raise money, the investment arms of big pharma companies stepped in to fill a funding gap that was starving start-ups. Fast forward to the current period of plenty and, while corporate cash is no longer quite so crucial to the ecosystem, many of these units remain enthusiastic backers of early-stage science.

American Gene Technologies Signs Research Agreement with NIAID for Experimental HIV/AIDS Cure Strategy | American Gene Technology

American Gene Technologies (AGT) recently signed a Research Collaboration Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, for research studies on AGT’s cell and gene therapy for HIV/AIDS. AGT uses its proprietary, genetically modified, autologous cell product (AGT103-T) to reconstitute the immune response against HIV with the goal of reducing persistent viral reservoirs and achieving sustained virologic remission in infected individuals in the absence of antiretroviral therapy. Under this collaboration agreement, NIAID researchers will study the mechanism of action for AGT103-T to define its potential impacts on HIV disease.

BioHealth Innovation Entrepreneur-in-Residence Feedback – Feb. 27th

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan? Sign up now to schedule your feedback session with BHI Entrepreneurs in Residence next Wednesday, February 27th. (Future sessions scheduled for 3/20 and 5/22.) Pre-registration is required; sign up here (“EIR resource” at BHI). For questions/more information, contact BHI.

2-28 SBIR & Non-Dilutive Funding Workshop Agenda Set!

University of Maryland Institute for Bioscience & Biotechnology Research, 9600 Gudelsky Drive, Rockville, MD 20850

Register NOW: https://tinyurl.com/BHISBIR2019

8:00 a.m. – Networking and Registration
8:30 a.m. – Welcome
8:35 a.m. – SBIR Funding Opportunities at the National Institutes of Health
- National Heart, Lung, and Blood Institute
- National Institute on Aging
- National Institute on Drug Abuse
- National Cancer Institute
9:45 a.m. – Partnership Opportunities with NCI Frederick National Lab
10:00 a.m. – BREAK
10:20 a.m. – SBIR Funding Opportunities with the National Science Foundation
11:00 a.m. – BREAK
11:15 a.m. – SBIR Funding Opportunities with USAMRC
11:45 a.m. – Lunch
12:45 p.m. – (1:1 Room Set)
1:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
1:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously)
2:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
2:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously))
3:00 p.m. – 1:1 Meetings* (NIH only)
4:00 p.m. – Adjourn

Pre-Registration REQUIRED: RSVP by noon, February 26 at https://tinyurl.com/BHISBIR2019No charge for entrepreneurs to attend • If seeking 1:1 meeting(s) please include organization(s) in RSVP.

Johns Hopkins Team to Commercialize Barrett’s Esophagus Epigenetic Biomarker Panel | GenomeWeb

A team of researchers led by the Johns Hopkins University of Medicine has developed a methylated epigenetic biomarker panel integrating a sponge-based collection tool and a methylated-bead PCR method that it believes can detect Barrett’s esophagus (BE).

Emergent BioSolutions (EBS) Appoints Seamus Mulligan to Board

Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Seamus Mulligan to the company’s Board of Directors effective March 19, 2019. Mr. Mulligan was a co-founder and principal investor of Adapt Pharma Ltd. and served as its chairman and CEO from 2014 until 2018, when Adapt was acquired by Emergent.

A $3.6 million grant will help UMD researchers advance cancer research – Arc Publishing

The National Institute of Health awarded a University of Maryland research center team of scientists $3.6 million to help fund their work on the cells responsible for destroying cancer cells.

QIAGEN partners with Ares Genetics to advance global fight against antibiotic-resistant pathogens – MarketWatch

QIAGEN N.V. today announced a broad agreement with Ares Genetics, a subsidiary of Curetis N.V. CURE, -0.10% to develop innovative bioinformatics and assay solutions to accelerate research targeting the growing global health challenges posed by antibiotic-resistant bacteria.

Frederick-based Akonni Biosystems Awarded $3M NIH Phase 2 Award to Develop Low-Cost Tuberculosis Test

Akonni Biosystems, a molecular diagnostics (MDx) company that develops, manufactures, and intends to market advanced MDx systems, today announced receipt of a $3 million, three-year Phase II Small Business Innovation Research (SBIR) contract from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). Akonni received the Phase I contract in August 2016.

Kousouris, Bailey Take New Leadership Roles at JHTV – JHTV

Steve Kousouris, who has been serving as Interim Executive Director of Technology Transfer at Johns Hopkins Technology Ventures since June, has assumed this role permanently effective Jan.1. Additionally, Mark Bailey, previously Associate Director of Finance, will assume responsibility for the portfolio that Steve has overseen since 2013 in the capacity of Director, Finance & Administration.

Kelly M. Schulz, State Secretary of Commerce – I95 Business

Kelly M. Schulz, the newly appointed state secretary of commerce, could be called the secretary of opportunity. Her vision for the state of Maryland is for economic development, job growth, full employment and economic prosperity for all families around the state.

Is that a robot? Dr. Bear Bot helps care for kids at local hospital. – The Washington Post

“How did you get in the robot?” That was the question a young patient at Children’s National Health System had on Thursday for Dr. Bear Bot.

18 charts to illustrate US VC in 2018 – PitchBook

Over the past couple of years, the term “record-breaking” has frequently been used to describe the state of venture capital in the US, as the space hits new heights with deal value, mega-rounds and fundraising. In 2018, some of these records reached heights not seen since the dot-com boom.

Pioneering Physician-Scientist to Receive 2019 Szent-Györgyi Prize for Progress in Cancer Research

The National Foundation for Cancer Research (NFCR) announced today that Steven A. Rosenberg, M.D., Ph.D., of the U.S. National Cancer Institute (NCI) has been selected to receive the 2019 Szent-Györgyi Prize for Progress in Cancer Research. The Prize selection committee awarded Dr. Rosenberg for not only revolutionizing—if not originating—the field now known as cancer immunotherapy but also remaining at its forefront. Chief of the NCI Center for Cancer Research’s surgery branch in Bethesda since 1974, his basic, translational and applied research efforts have contributed immeasurably to groundbreaking advances in therapy and the later development of drugs such as Chiron’s (later Novartis and Prometheus Labs’) Proleukin, Bristol-Myers Squibb’s Yervoy and Gilead’s Yescarta.

Unlucky 13: Top Clinical Trial Failures of 2018

Nuventra Pharma Sciences, a clinical pharmacology and PK/PD consultancy in Durham, NC, recently offered some insights on why clinical trials fail. In addition to biological considerations—such as pharmacokinetics, pharmacodynamic, and human response to a drug varying from animal models—Nuventra presented a list of reasons that included:

7 takeaways from HIMSS 2019 – MedCity News

Friday is the official last day of #HIMSS19 in Orlando. The annual healthcare conference, which began on Monday, February 11, was packed full of presentations, panels, products and people.

Novak Biddle from Roger Novak, Jack Biddle officially closes up shop – Washington Business Journal

The 22-year-old firm has invested in a number of well-known local companies.

Feb 28 2019

Love0

341st Edition – February 12, 2019

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

February 12, 2019

FOUNDING MEMBER OF

FOURTH ANNUAL CRAB TRAP COMPETITION

NOW ACCEPTING APPLICATIONS at

https://form.jotform.com/90276838255163

Submit your application by March 1st for a chance to be named

‘the company with the most commercial potential’

at the BioHealth Capital Region Forum

Deadline for entries is March 1, 2019

Finalists will be announced March 21, 2019

Present at BioHealth Capital Region Forum April 9, 2019.

Finalists will have a chance to win the grand prize by presenting in front of a panel of world-class judges.

PRIZES

Grand Prize provided by WSGR $10,000

Visibility in front of hundreds of industry leaders and prominent industry funding experts and executives.

CRITERIA

Product, Technical Feasibility, Marketing/Strategy, Leadership Team, Financial/Projection

Startup CXO Database

Are you an experienced biohealth entrepreneur seeking new opportunities in the BioHealth Capital Region? BioHealth Innovation is developing a database of experienced industry personnel willing to work in potential C-suite positions with our university and startup partners. If you would like to have your contact information and vita included in this database for their review, please email BHI an updated vita by this Thursday, February 14th.

Brian Darmody Announced as AURP CEO & Launches ‘AURP HQ2’ in Washington, DC Area

The Association of University Research Parks (AURP), a professional association of university-related research and science parks, announced the appointment of Brian Darmody, Associate Vice President of Corporate Engagement at the University of Maryland (UMD), as its new Chief Executive Officer (CEO). Additionally, the association has opened a new office at the UMD Discovery District in the Washington, DC area, to be known as ‘AURP HQ2.’ Mr. Darmody will immediately assume his new role as CEO at the new location. He will continue his role at UMD and plans to transition out of UMD over time.

BioHealth Innovation Entrepreneur-in-Residence Feedback – Feb. 27th

Are you a start-up in Maryland, DC or Virginia seeking feedback on your biohealth business idea, pitch deck, or commercialization plan. Sign up now to schedule your feedback session with BHI EIRs on Wednesday, February 27th. (Next sessions scheduled for 3/20 and 5/22.) Pre-registration is required; sign up here (“EIR resource”at BHI). For questions/more information, contact BHI.

2-28 SBIR & Non-Dilutive Funding Workshop Agenda Set!

University of Maryland Institute for Bioscience & Biotechnology Research, 9600 Gudelsky Drive, Rockville, MD 20850

Register NOW: https://tinyurl.com/BHISBIR2019

8:00 a.m. – Networking and Registration
8:30 a.m. – Welcome
8:35 a.m. – SBIR Funding Opportunities at the National Institutes of Health
- National Heart, Lung, and Blood Institute
- National Institute on Aging
- National Institute on Drug Abuse
- National Cancer Institute
9:45 a.m. – Partnership Opportunities with NCI Frederick National Lab
10:00 a.m. – BREAK
10:20 a.m. – SBIR Funding Opportunities with the National Science Foundation
11:00 a.m. – BREAK
11:15 a.m. – SBIR Funding Opportunities with USAMRC
11:45 a.m. – Lunch
12:45 p.m. – (1:1 Room Set)
1:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
1:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously)
2:00 p.m. – Writing Your Specific Aims Page OR 1:1 Meetings* (available simultaneously)
2:30 p.m. – Writing Your Phase II Commercialization Plan OR 1:1 Meetings* (available simultaneously))
3:00 p.m. – 1:1 Meetings* (NIH only)
4:00 p.m. – Adjourn

Pre-Registration REQUIRED: RSVP by noon, February 26 at https://tinyurl.com/BHISBIR2019No charge for entrepreneurs to attend • If seeking 1:1 meeting(s) please include organization(s) in RSVP.

MacroGenics’ stock price more than doubles on successful breast cancer study – MedCity News

Shares of MacroGenics went stratospheric Wednesday following the release of data from a pivotal Phase III study of the company’s lead drug candidate in breast cancer that beat many investors’ expectations.

VLP Therapeutics to Initiate First Clinical Trial of VLPM01 Malaria Vaccine

VLP Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a clinical trial of the Company’s VLPM01 malaria vaccine. The Phase I/IIa clinical trial will begin recruiting participants in February 2019, and is designed to assess the safety, immunogenicity and efficacy of the VLPM01 vaccine. The clinical trial will be conducted at the Walter Reed Army Institute of Research (WRAIR) in Silver Spring, MD.

US FDA grants Breakthrough Therapy Designation for potential next-generation RSV medicine MEDI8897

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for MEDI8897, an extended half-life respiratory syncytial virus (RSV) F monoclonal antibody (mAb) being developed for the prevention of lower respiratory tract infection (LRTI) caused by RSV.

The United States Of Venture Capital: The Most Active VC In Each State

Although startups based in California, New York, and Massachusetts have traditionally accounted for the majority of VC tech investment in the US, VCs are spurring other hotbeds of innovation across the country.

New Lab Space Designed to Attract Biotech Talent and Community Opens at 704 Quince Orchard – BioBuzz

When construction is completed this month, 704 QO will offer ready-to-occupy lab/office spaces for companies of all sizes. What really makes this new building stand out isn’t just the fully customizable individual lab units, but the suite of amenities that are tailored to the specific needs of emerging life science companies in the BioHealth Capital Region and the employees that work for them.

Look back at 10 of Baltimore tech’s biggest moments of the last decade – Technical.ly Baltimore

Today we’re celebrating around the Technical.ly Slack channel. It’s the 10th anniversary of Technical.ly’s founding in Philadelphia, marking a decade of local tech news and innovation community coverage.

PitchMasters™ hosts four emerging startups at January event, expands to Baltimore and New York – Shulman Rogers

PitchMasters™, a workshop-style event for entrepreneurs preparing for their first institutional capital raise, held its 2019 Kick Off and Alumni Event on Jan. 30, 2019. Four emerging startup companies, Skipiit, Trove Therapeutics, Uplift and VERALOX Therapeutics, practiced their pitching skills and gained insights from experienced entrepreneurs, investors, industry influencers and fellow PitchMasters™ alumni.

Growth In Life Sciences Innovation Triggers Demand For Real Estate Clusters

The life sciences industry is taking off, with the medical technology and biotech sectors expected to grow further as traditional pharmaceutical companies are joined by startups and incubator labs driving new research and development. And with life sciences innovation rising, so is demand for the space in which to innovate.

Beyond Wellness For the Healthy: Digital Health Consumer Adoption 2018 – Rock Health

Utilization of digital health services and technologies has been on the rise since we first began surveying the US adult population in 2015. Budding choices of wearables, apps, telemedicine, and other tech-enabled services make it easy for consumers to test out what it might be like to “go digital” for their health. In the first three years, our annual survey showed that tools for fitness and wellness represented a common (and low-risk) entry point for consumers to experiment with products that fit neatly into their already tech-enabled lifestyles. In the 2018 data that we examined for this report, we saw something different.

Feb 05 2019

Love0

340th Edition – February 5, 2019

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

February 5, 2019

FOUNDING MEMBER OF

FOURTH ANNUAL CRAB TRAP COMPETITION

NOW ACCEPTING APPLICATIONS at

https://form.jotform.com/90276838255163

Submit your application for a chance to be named

‘the company with the most commercial potential’

at the BioHealth Capital Region Forum.

Deadline for entries is March 1, 2019

Finalists will be announced March 21, 2019

Present at BioHealth Capital Region Forum April 9, 2019.

Finalists will have a chance to win the grand prize by presenting in front of a panel of prominent industry funding experts and executives.

Moderator – Rich Bendis, President and CEO, BioHealth Innovation
2019 Judges to be announced

PRIZES

Grand Prize provided by WSGR $10,000
Visibility in front of hundreds of attendees and prominent industry and venture capital judges

CRITERIA

Product
Technical Feasibility
Marketing/Strategy
Leadership Team
Financial/Projection

Dr. Julia Finkel, Pediatric Anesthesiologist, Children’s National Medical Center, joins Biotalk host Rich Bendis

Dr. Julia Finkel, Pediatric Anesthesiologist, Children’s National Medical Center, joins Biotalk host Rich Bendis to discuss pain care management, the founding of startup AlgometRx, and the funding of this new companyDr. Julia Finkel, Pediatric Anesthesiologist, Children’s National Medical Center, joins Biotalk host Rich Bendis to discuss pain care management, the founding of startup AlgometRx, and the funding of this new company.

Julia Finkel, M.D., is a pediatric anesthesiologist and director Pain Medicine Research and Development in the Sheikh Zayed Institute for Pediatric Surgical Innovation.

Dr. Finkel has extensive experience designing and conducting clinical trials relating to analgesics in children and has received both industry and federal funding of her research. Dr. Finkel is regularly invited to speak at national meetings on topics related to pediatric pain management.

Listen now on iTunes , Google Play , and TuneIn.

SBIR & Non-Dilutive Funding Workshop – February 28th

UMD IBBR – 9600 Gudelsky Drive, Rockville, MD 20850

February 28, 2019

Unique opportunity to meet 1:1 with multiple SBIR program managers and experts.

SCHEDULE

8:00 a.m. – 8:30 a.m. – Networking and Registration
8:30 a.m. – 12:00 p.m. – Program Overviews. Agencies represented:
- NSF (National Science Foundation)
- NIH NIA (National Institute on Aging)
- NIH NCI (National Cancer Institute)
- NIH NHLBI (National Heart, Lung, and Blood Institute)
- NIH NIDA (National Institute on Drug Abuse)
- US Army (invited)
12:00 p.m. – 1:00 p.m. – Networking Lunch
1:00 p.m. – 1:30 p.m. – Writing Specific Aims Page
1:30 – 2 p.m. – Writing Your Phase II Commercialization Program
2:00 – 2:30 p.m. – Q&A with All speakers
2:30 – 4:00 p.m. – 1:1 – Meetings with Program Managers*

Pre-Registration REQUIRED: RSVP by noon, February 26 at https://tinyurl.com/BHISBIR2019

No charge for entrepreneurs to attend • If seeking 1:1 meeting(s) please include organization(s) in RSVP.

*You do not have to participate in 1:1 meetings. However, to do so, you must attend the overview session in person.

Scoop: GSK’s venture team at SR One in talks to spin off from its big pharma founder, now under new R&D management – Endpoints News

The partners at SR One, a storied corporate biotech VC with investments across a wide range of drug developers on both sides of the Atlantic, are engaged in talks to split away from the pharma giant GlaxoSmithKline, according to sources familiar with a move that’s been in the works since at least late last year.

Cerecor Announces U.S. Headquarters Move Into Pharmaceutical Corridor of Rockville, Maryland

Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments in rare and orphan diseases in pediatrics and neurology, announced today that it has moved its U.S. Corporate Offices to 540 Gaither Road Suite 400 located in Rockville, Maryland. The company had previously been based in Baltimore, Maryland.

Montgomery County Economic Development Corporation Renews Support Commitment to Maryland Tech Council’s Venture Mentoring Services Program

Maryland Tech Council (MTC) announced today that the Montgomery County Economic Development Corporation (MCEDC) will continue its partnership with and support of MTC’s Venture Mentoring Services (VMS) program. MCEDC has funded the mentoring program for three years and will continue to support it in 2019-to further augment the growth of Montgomery County’s target industries-technology and life sciences, while providing a key component to sustain economic growth in the County.

GetWellNetwork poised to increase global footprint and drive digital health innovation across care continuum in 2019 | GetWellNetwork

GetWellNetwork, the Precision Engagement health care company reaching 10 million patients annually, announced today a pivotal 2018 which will propel the company into 2019 as it continues to lead the evolution of patient engagement. The company furthered global expansion efforts, made several executive hires and acquired leading digital health company HealthLoop to catalyze growth in the ambulatory space.

2018 Global Digital Health 100 – emocha included

Explore the 2018 Global Digital Health 100.

The Global Digital Health 100 is one of the HealthTech industries foremost technology awards programmes, celebrating innovation and entrepreneurship. It recognises and supports health technology companies that are demonstrating the greatest potential to change the way that healthcare is delivered.

Rexahn Receives Notice of Allowance for U.S. Patent Covering RX-3117 Use in a Broad Range of Tumor Types – Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 15/683,408, “Fluorocyclopentenylcytosine Methods of Use.” The patent application covers the use of RX-3117 in a broad range of tumor types that over-express UCK2, the enzyme that activates RX-3117. The company expects the patent to be issued within a few months from the notice of allowance and provide protection to 2036.

Viela Bio, NextCure among Maryland companies that received most VC funding in 2018. – Baltimore Business Journal

The top company received more than $280 million VC funding in 2018.

Billion-dollar year: Maryland builds venture capital momentum with record-breaking 2018 – Baltimore Business Journal

Seven firms brought in over $30 million last year, and five raised more than $70 million in venture capital.

Q4 2018 I-270 Lab Market Report

The extremely active lab real estate market is a bell-weather for the upcoming hyper-competitive talent market. Based on the recent real estate transactions and related hiring forecasts, we estimate the range of new positions in the Maryland life sciences market to be between 1,150 to 2,300 new hires in 2019.

Infographic: Visualizing the Future of the Pharma Market

By 2050, there will be two billion people that are 60 years or older globally. Meanwhile, the amount of seniors (65+ years old) in the U.S. will double to 100 million by 2060.

MdBio Foundation changes name to Learning Undefeated amid national expansion – Technical.ly Baltimore

In a move to reflect the reach into more states it has gained in recent years, MdBio Foundation unveiled a rebrand as Learning Undefeated on Tuesday.

FITCI is a incubator and accelerator for science and technology-based business.

Community members gathered Wednesday night at Hood College’s Hodson Auditorium to celebrate Frederick Innovative Technology Center Inc.’s 15th anniversary.

VitusVet, eying growth, hires OrderUp cofounder as COO – Technical.ly Baltimore

Like a lot of medical practices, veterinarians seek to send patients a message when they’re due for a check-up, schedule appointments and keep track of medical records. Yet Marc Olcott sees a lot of those tasks still happening by phone or on paper, and thinks it should all be available digitally.

Here are this year’s 20 most promising startups in Baltimore: realLIST 2019 – Technical.ly Baltimore

For the people looking to move within a thriving tech community, it’s important to be able to easily call upon the key players.

Equity Crowdfunding for Biotech Startups: Does it Work?

In the last decade, crowdfunding has become a popular way to finance all sorts of projects and products. Biotech is no exception, but many question whether the high risk and long term nature of investing in the biotech industry makes it a good fit for equity crowdfunding.

Keiretsu Forum Mid-Atlantic Partners and CONNECTpreneur to Advance Innovation and Entrepreneurship – Press Release – Digital Journal

The premier investor network in the Mid-Atlantic has entered into a resource partnership. Keiretsu Forum Mid-Atlantic and the CONNECTpreneur community have entered into an agreement that will advance innovation, entrepreneurship, and investment in the region.

Lung Cancer May Be Sniffed Out Earlier with Graphene e-Nose

Lung cancer may not be the first thought that crosses the mind when talking about breathalyzer tests. But, what if lung cancer detection were as easy as breathing into a device? That is the goal of a group of researchers from the University of Exeter who have recently taken a new approach to e-nose technology integrated with multi-layered graphene for early detection of lung cancer.

Accelerating Swiss innovations to market with strategic collaboration

Catalyze announces collaboration with Biopôle, providing dedicated services to members towards better access to non-dilutive funding opportunities.

Feb 05 2019

Love0

339th Edition – January 29, 2019

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

January 29, 2019

FOUNDING MEMBER OF

Win $ and Visibility in Front of Hundreds of Attendees at the 2019 BHCR Crab Trap

You thought the Shark Tank was tough…Wait until you enter the the BioHealth Capital Region Crab Trap!

Submit your application for the opportunity to present your innovation and be named the region’s early stage biohealth company with the most commercial potential at the 2019 BioHealth Regional Forum, $10,000, and MORE!

Application Deadline: March 1, 2019

Finalists will be announced: March 21st, 2019

Finalist Presentations BioHealth Capital Region Forum event: April 9th, 2019

Submit Application »

MaxCyte: Driving New Generation of Cell-Based Medicines – WXPress – Global open-access R&D enabling platform, life science industry news and perspectives

Cell therapy offers a treasure chest of new medicines, but there is still much to learn about cell activities and how to deliver these potential benefits before science and the industry can fully fulfill on their promise. One of cell therapy’s earliest pioneering companies is MaxCyte, based in Gaithersburg, MD and in the United Kingdom. Leading MaxCyte is president and CEO Doug Doerfler, a biotech pioneer who has more than 35 years of experience in the discovery, development, commercialization and international financing of biotechnology products and companies. He was also a founder of MaxCyte in July 1998.

Emocha wants to help Type 2 diabetes patients stick to their drug regimens

This new program is specifically aimed at helping patients with Type 2 diabetes, who take medications to control their blood sugar levels.

United Therapeutics Announces Closing Of License Agreement With Arena Pharmaceuticals For Ralinepag

United Therapeutics Corporation (Nasdaq: UTHR) today announced the closing of the transactions contemplated by its license agreement with Arena Pharmaceuticals, Inc. (Nasdaq: ARNA). Under the agreement, United Therapeutics acquired exclusive, worldwide rights to develop and manufacture the Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH). Upon closing, United Therapeutics paid Arena $800 million. Arena is also entitled to potential milestone payments of up to $400 million based on the achievement of certain regulatory events as well as low double-digit tiered royalties on annual net sales of ralinepag products.

SBIR and Other Non-Dilutive Funding Sources – February 28

HOLD THE DATE – February 28, 2019 8 am. – 3:00 p.m.

Meet 1:1 with SBIR program managers. Learn more about their funding programs (SBIR and more!)

8-8:30 Networking and Registration

8:30 – 12:00 p.m. – Program Overviews

12:00 p.m. – 1:00 p.m. – Networking Lunch

1:00 p.m. – 3:00 p.m – 1:1 Meetings with Program Managers*

Agencies represented include: NSF, NIH NIA, NIH NCI, NIH NHLBI, NIH NIDA, US Army (invited)

*The program overview will be available by videoconference.

**You do not have to participate in 1:1 meetings. However, to do so, you must attend the overview session in person.PRE-REGISTRATION IS REQUIRED: RSVP by noon 2/26: BHI@BioHealthInnovation.org

Well Doc’s BlueStar highlighted on Forbes’ list of Digital Healthcare Growth Drivers

The digital transformation of healthcare will see significant growth in the next 12 months fueled by institutional interest in driving down costs and improving patient engagement. Expect increased pharma investment, improving regulatory status, payer engagement with digital tools and better telemedicine connectivity through consolidation.

Maryland E-Nnovation initiative provides matching funds for tech-focused research endowments – Technical.ly Baltimore

Four Maryland colleges are expanding tech-focused programming with funding from a state program.

The Maryland E-Nnovation Initiative Fund was created to spur research in scientific and technical fields at colleges and universities in the state.

Report: Most investment in DC-area cybersecurity startups goes to Maryland, Virginia – Technical.ly DC

Washington, D.C.–based cybersecurity investment firm Strategic Cyber Ventures released its first annual report on The State of 2018 Cybersecurity Investing that includes some key findings about the DMV.

GCTCI: Washington DC ranked as the top city globally for talent competitiveness

Washington, D.C. has been crowned as the city that’s leading the way in talent competitiveness, thanks to its ability to attract and nurture entrepreneurs, whilst meeting the needs of being a strongly-connected, “global” city.

Scoop: GSK’s venture team at SR One in talks to spin off from its big pharma founder, now under new R&D management – Endpoints News

Education Top Budget Priority For Maryland With Record Funding For 2020 – CBS Baltimore

Gov. Hogan’s new fiscal 2020 budget is officially on the table, and it’s getting a preliminary thumbs up from the Democratic leadership in the General Assembly.

This year’s budget may go above and beyond when it comes to kids.

gel-e Expands Patent Estate with Next Level of Exclusivity

gel-e Inc., announces the issuance of United States Patent Number 10,179,145 by the U.S. Patent and Trademark Office, which broadly claims and discloses uses of the Company’s core technology.

Over-regulating drugs threatens Md. Life sciences industry – Baltimore Sun

One major focus for legislators during this year’s session is how to bring down the cost of health care, as everyday Marylanders struggle to afford the cost they pay at the pharmacy counter. Despite disagreements between different groups within and beyond health care, there is broad consensus that something must be done about the cost patients pay without denying Marylanders the world-class treatments available to them, many of which are made right here in Maryland.

Demystifying industry–academia collaboration

The past decade has seen intensified research collaboration between pharmaceutical companies and academic institutions. Although such partnerships are recognized as a source of innovation and a key pillar to advance science in drug discovery, they are replete with challenges. Despite much anecdotal evidence and debate, fact-based evidence on the nature of these challenges and how to manage them is scarce.

The State of Health Care Innovation in 2019: The World Awaits – LinkedIn

2019 has kicked off with a wave of innovative health care solutions highlighted at mega-conferences like CES and the J.P. Morgan Healthcare Conference – from the introduction of the first wearable blood pressure monitor to virtual home health care for seniors to online vision tests allowing patients to renew prescriptions from anywhere at anytime. We are truly living through an age of disruption spurred by technological advances.

10 Takeover Targets to Watch in 2019

After weeks of speculation that biopharma deal making would cool off, 2019 got off to a flying start as far as mergers-and-acquisitions (M&A) is concerned, thanks to two blockbuster transactions: Bristol-Myers Squibb’s planned $74 billion acquisition of Celgene, followed four days later by Eli Lilly’s planned $8 billion purchase of Loxo Oncology—a deal that quickly became the buzz of the J.P. Morgan 37th Healthcare Conference, held earlier this month in San Francisco.

Spring 2019 NCI-UMD Partnership for Integrative Cancer Research Symposium

Our National Cancer Institute-University of Maryland (NCI-UMD) Partnership for Integrative Cancer Research reflects the broad interests of our participating NCI and UMD researchers. We are delighted to invite you to our annual NCI-UMD Partnership for Integrative Cancer Research Symposium on Friday, February 8th from 10am-4pm which will take place in Bethesda, Maryland in the John Edward Porter Neuroscience Research Center at the National Institutes of Health, Bldg 35A, Room 620/630. Please register and plan to participate in our October symposium. The final agenda will be announced shortly.

Jonathan Aberman: Why are we using Silicon Valley’s entrepreneurship model? – Washington Business Journal

We need to chart a new course.

Diet, the Gut Microbiome, and Colorectal Cancer: Are They Linked?

Colorectal cancer (CRC) is one of the leading causes of death in the western society, being ranked third most lethal neoplasia in the United States in both men and women.1 In 2014, the American Cancer Society estimated that approximately 136,830 new cases of CRC will be diagnosed in the United States, with more than 50,000 Americans expected to die due to disease progression or complications.1,2 The lifetime cancer-related costs are considerable and differ by cancer site, disease stage, age at diagnosis, and treatment phase. Considering direct healthcare costs, CRC is the second most important neoplasia with estimated expenses of more than $14 billion.3,4

Deloitte named world’s most valuable professional services brand | Deloitte China | Newsroom

Deloitte has surpassed its peers to become the world’s most valuable professional services brand, according to the 2019 Global 500 report issued by Brand Finance on 22 January 2019. Deloitte’s strong performance was due to higher scores in Brand Finance’s metrics of familiarity, consideration, satisfaction, preference, recommendation and revenue.

First CRISPR Clinical Trial Begins in Europe | Scienceline

The highly touted gene-editing technology CRISPR is facing one of its first real-world tests. As many as 12 patients who live with the blood disorders sickle cell anemia or beta-thalassemia have started enrolling in a Europe-based clinical trial that may serve as an early indicator of whether gene editing will live up to the hype.

Jan 28 2019

Love0

338th Edition – January 22, 2019

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

January 22, 2019

FOUNDING MEMBER OF

William E. Bentley, Professor of Engineering and Founding Director of the Fischell Institute for Biomedical Devices joins Rich Bendis for the first BioTalk of 2019

William E. Bentley is the Robert E. Fischell Distinguished Chair of Engineering and the Inaugural Director of the Robert E. Fischell Institute for Biomedical Devices. He is appointed in the Fischell Department of Bioengineering as well as the Department of Chemical and Biomolecular Engineering at the University of Maryland, College Park and the Institute for Bioscience and Biotechnology Research. At Maryland since 1989, Dr. Bentley has focused his research on the development of molecular tools that facilitate the expression of biologically active proteins and on materials incorporated into biomedical devices, having authored over 300 related archival publications

He is a fellow of AAAS, ACS, AIMBE, and the American Academy of Microbiology. He has served on advisory committees for the NIH, NSF, DOD, DOE, FDA, USDA, and several state agencies and has mentored over 40 PhDs and 25 postdocs, many now in leadership roles within industry (24), federal agencies (5) and academia (26). He co-founded a protein manufacturing company, Chesapeake PERL, based on insect larvae as mini bioreactors.

Listen now on iTunes , Google Play , and TuneIn.

Viela Bio on BioSpace Top 20 Life Sciences Companies to Watch

BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.

Alexandria and NEA Number 1 and 2 in List of VC Firms That Made the Most Investments in Healthcare Startups in 2018

To those who have been following the space, it’s no surprise that 2018 has been a record year for venture capital investing in healthcare. With $28.8 billion raised through the end of November (and big deals like the $400 million Series C raised by Relay Therapeutics last week) startups in the sector have raised more money this year than any year before in the last 10 years that VC funding database Pitchbook has tracked investments in the space.

Lupin receives FDA approval for Levothyroxine Sodium Tablets USP – Lupin

Pharma major Lupin announced that it has received approval for its Levothyroxine Sodium Tablets USP, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg from the United States Food and Drug Administration (FDA) to market a generic version of AbbVie, Inc’s Synthroid Tablets, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg.

Maryland’s Vitus Vet #1 App for Pet Owners

There’s an app for everything these days — including a plethora for people with pets.

Thanks to the streamlined design of most current apps, you don’t have to be technically savvy to know how to download and use them on your smartphones or tablets.

Tax Implications and Accounting Issues for Start-Ups — January 23rd

Join us for the January 23, 2019 for PATHFINDER INNOVATION PROGRAM

Learn more about:

Overview and Reporting Requirements for Type of Entity
Impact of Accounting Methods
Start-up Company Issues
International Investment
Tax Law Changes
State Tax Concerns
Tax Planning

Schedule

12:00 p.m – Networking Lunch

12:30 – 1:30 p.m. – Discussion with Q&A* – Tom Christiana, Partner – Aronson, LLC

1:30 – 4:00 p.m. – One-on-one Meetings**

RSVP by noon, January 22, at BHI@BioHealthInnovation.org

No charge to attend but pre-registration is required.*Attend in person (1 Church St, Rockville) or by videoconference**Attendance at discussion is required to participate in 1:1

Download Flyer »

Alexandria Real Estate buys Jazz Pharmaceuticals-leased Stanford Research Park building at 3170 Porter Drive – Silicon Valley Business Journal

Biotech landlord and developer Alexandria Real Estate Equities has purchased an office complex in Palo Alto’s Stanford Research Park from Stanford University for $100.3 million.

Maryland companies raised more than $1B in venture funding in 2018 – Technical.ly Baltimore

Maryland’s overall venture capital haul for 2018 totaled crossed the billion-dollar mark for the first time since 2001, according to the PwC/CB Insights MoneyTree report.

MCEDC Welcomes Bill Tompkins — MCEDC

The Montgomery County Economic Development Corporation (MCEDC) and its board are pleased to welcome Bill Tompkins as Chief Operating Officer. Bill brings to Montgomery County a strong corporate and trade association background, having served in multiple senior level roles for Fortune 500 and other organizations.

Johns Hopkins, health tech Emocha win CDC funding to study effect of financial incentives on addiction recovery – Baltimore Business Journal

Study participants will use emocha’s platform to video record themselves each day for 24 weeks as they take buprenorphine.

Maryland ranks No. 3 for contribution to tech economy – Baltimore Business Journal

Milken Institute publishes its 2018 State Technology and Science Index.

Popper and Company Adds Diagnostic Industry Leaders as Senior Advisors

Popper and Co., a strategy consulting and transaction advisory firm guiding medical technology and life sciences companies working on the leading-edge of diagnostics and patient management, announced today the addition of Vincent Linder, PhD and Gene Vivino to its growing team of industry and clinical senior advisors. Both Dr. Linder and Mr. Vivino provide strong industry knowledge and extensive operating experience, in addition to broad networks in both Europe and Asia.

Small Business Network: Making Montgomery County Business Friendlier – YouTube

Montgomery County Executive Marc Elrich and Council President Nancy Navarro are the guests of Montgomery Community Media’s January Small Business Network (SBN) session.

Well Doc’s BlueStar highlighted on Forbes’ list of Digital Healthcare Growth Drivers

Protenus to expand, move HQ to Brown’s Wharf in Fells Point – Baltimore Business Journal

The health data security company has outgrown its offices near Little Italy.

Maryland universities propose new programs – Maryland Daily Record

Maryland universities are creating new academic programs they say could help the state adapt to a changing innovation economy and help meet needs for tomorrow’s educators. The Education Policy and Student Life committee of the University System of Maryland’s Board of Regents moved forward this week with eight new programs proposed from system universities.

Hopkins researchers to study whether financial rewards, video monitoring can help opioid addiction treatment – Baltimore Sun

Researchers at the Johns Hopkins University School of Medicine have been awarded $2.1 million by the U.S. Centers for Disease Control and Prevention to study whether paying patients to take their medicine and tracking their doses with video software can help patients stick with their treatment for opioid addiction.

Economic Alliance of Greater Baltimore taps Michele Whelley as new CEO – Baltimore Business Journal

The hire is well known in the business community for her previous roles at local organizations.

Pappas Capital raises $85.8 mln for venture-capital fund – PE Hub

Pappas Capital has raised $85.8 million toward a venture-capital fund, according to a filing with the SEC.

A. M. Pappas Life Science Ventures V attracted capital from 29 LPs.

Attendees fed up with venue, high prices call to move JPM out of San Francisco | FierceBiotech

While the high cost of living in San Francisco has famously grabbed headlines, the costs of simply meeting there, even for a few days, are becoming untenable for some.

As 9,000 official badge holders—alongside what could feel like three times as many unofficial attendees—swarmed downtown San Francisco for the annual J.P. Morgan Healthcare Conference, much of the opening small talk in the hastily bedless hotel suites-turned-meeting rooms began with, “Can you believe some of these prices?”

BIO launches Innovature, a new platform to support innovation in food and agriculture

BIO, in partnership with the American Seed Trade Association (ASTA), is proud to announce today that we are launching Innovature, an initiative to engage people in a dialogue on the promise of innovation in food and agriculture and the tangible benefits it brings to our planet, our health, and our food.

The goal of Innovature is to grow awareness, acceptance and adoption of gene editing in food and agriculture, and seed positive ground for future innovations that address some of society’s most pressing challenges, such as climate change, hunger and sustainability.

For CAR-Ts to be successful, figuring out manufacturing is key – MedCity News

To date, the conversation around CAR-T cell therapies in cancers has focused on the most visible considerations: efficacy, toxicity and cost. But while those factors are important, another one deserves equal consideration: manufacturing.

Press Announcements > Statement from FDA Commissioner Scott Gottlieb, M.D. and Peter Marks, M.D., Ph.D., Director of the Center for Biologics Evaluation and Research on new policies to advance development of safe and effective cell and gene therapies

The FDA is witnessing a surge of cell and gene therapy products entering early development, evidenced by a large upswing in the number of investigational new drug (IND) applications. Based on this activity, we anticipate that the number of product approvals for cell and gene therapies will grow in the coming years, reflecting significant scientific advancement and the clinical promise of these new innovations.

Frederick’s diversified life sciences and bio industry | Maryland Business News

Without a doubt, Frederick’s life sciences and biotechnology industry is closing out the year with strong growth, and starting 2019 with a solid foundation built on numerous innovative organizations and several areas of expertise.

BRCA Exchange aggregates data on thousands of BRCA variants to inform understanding of cancer risk | National Institutes of Health (NIH)

A global resource that includes data on thousands of inherited variants in the BRCA1 and BRCA2 genes is available to the public. The BRCA Exchange was created through the BRCA Challenge, a long-term demonstration project initiated by the Global Alliance for Genomics and Health (GA4GH) to enhance sharing of BRCA1 and BRCA2 data. The resource, available through a website and a new smartphone app, allows clinicians to review expert classifications of variants in these major cancer predisposition genes as part of their individual assessment of complex questions related to cancer prevention, screening, and intervention for high-risk patients.

Why gene therapies don’t work for everyone

Growing up in Devon in the 1980s, brothers James* and Matt* had to be careful with their antics–a cut or bruise could land them in hospital.

New Clinical Trial Aims To Detect Cancer With A Quick Breathalyzer Test

Nowadays ‘liquid biopsies,’ the notion of detecting cancer using only a blood test to detect minute amounts of circulating tumor are fairly well-known. But what if not even a blood test was needed to detect cancer, merely a few lungfuls of air?

Jan 28 2019

Love0

337th Edition – January 15, 2019

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

January 15, 2019

FOUNDING MEMBER OF

BHI Names Healthcare Innovation Expert John Sullivan as New Entrepreneur-in-Residence for National Institutes of Health

BioHealth Innovation, Inc. (BHI) announced today that John P. Sullivan has joined BHI as a new Entrepreneur-in-Residence (EIR) for the National Institutes of Health (NIH), working with Ethel Rubin, PhD, ventures team head, to provide product, corporate and private investment strategy for NIH portfolio companies.

“We are pleased to have Mr. Sullivan join the team of EIRs serving NIH,” said Richard Bendis, BHI President and CEO. “His expertise in building, operating and acquiring health technology businesses will certainly be an asset as he works to provide the institution with industry insights and commercialization perspectives.”

Established with NIH in 2012, the EIR program is designed to connect NIH-funded start-ups with experienced industry experts who can help them maneuver through multi-disciplinary technical challenges and the business and regulatory environment to deploy new healthcare and biomedical technologies.

Autolus to create 170 jobs, invest $28M in new Rockville HQ – Baltimore Business Journal

Montgomery beat out Boston and the Philadelphia areas to win the project.

Open for Business! 1800+ BioHealth Jobs in Region

A sign of the BioHealth Capital Region’s industry growth is the increase in hiring taking place throughout the region. More than 1800 job opportunities are listed on BioHealth Innovation’s website (www.BioHealthInnovation.org/Jobs). Many with relatively young companies expanding their regulatory, manufacturing and R&D teams. To post positions, Email: BHI@BioHealthInnovation.org.

GSK: Advancing Global Vaccines from its Rockville campus – Success Stories — MCEDC

GlaxoSmithKline – Advancing the science of vaccines and improving lives around the world.

No stethoscope for pain: Scientists seek real way to measure

Is the pain stabbing or burning? On a scale from 1 to 10, is it a 6 or an 8?

Over and over, 17-year-old Sarah Taylor struggled to make doctors understand her sometimes debilitating levels of pain, first from joint-damaging childhood arthritis and then from fibromyalgia.

Autolus Therapeutics Enters Lease with Alexandria Real Estate Equities, Inc. for Future Commercial-Scale Manufacturing Site and U.S. Headquarters

Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has signed a long-term, full-building lease with Alexandria Real Estate Equities, Inc. (NYSE: ARE) for the construction and development of an 85,000 square foot build-to-suit facility to be located in the Shady Grove Life Sciences Center in Rockville, Maryland. The new facility will house offices for Autolus’ U.S.-based research and development, commercial and corporate functions and serve as its first full commercial-scale manufacturing center, with a planned capacity to produce 5,000 T cell therapies annually. In addition, Autolus has established a temporary U.S. headquarters in Rockville until the new facility is ready for occupancy, which is currently expected to occur in 2021.

Tax Implications and Accounting Issues for Start-Ups – January 23rd

Join us for the January 23, 2019 for PATHFINDER INNOVATION PROGRAM

Learn more about:

Overview and Reporting Requirements for Type of Entity
Impact of Accounting Methods
Start-up Company Issues
International Investment
Tax Law Changes
State Tax Concerns
Tax Planning

Schedule

12:00 p.m – Networking Lunch

12:30 – 1:30 p.m. – Discussion with Q&A* – Tom Christiana, Partner – Aronson, LLC

1:30 – 4:00 p.m. – One-on-one Meetings**

RSVP by noon, January 22, at BHI@BioHealthInnovation.org

No charge to attend but pre-registration is required.

*Attend in person (1 Church St, Rockville) or by videoconference

**Attendance at discussion is required to participate in 1:1

Download Flyer »

SBIR and Other Non-Dilutive Funding Sources – January 29th

HOLD THE DATE – January 29, 2019 8 am. – 12:30 p.m.

Meet 1:1 with SBIR program managers. Learn more about their funding programs (SBIR and more!)

8-8:30 Networking and Registration

8:30 – 10:00 a.m. – Program Overviews*

10:00 – 12:30 p.m. – 1:1 Meetings with Program Managers**

Agencies represented include: NSF, NIH NIA, NIH NCATS, NIH NCI, NIH NHLBI, NIH NIDA, US Army (invited)

*The program overview will be available by videoconference.

**You do not have to participate in 1:1 meetings. However, to do so, you must attend the overview session in person.PRE-REGISTRATION IS REQUIRED: RSVP by noon 1/27: BHI@BioHealthInnovation.org

Johns Hopkins Technology Ventures Leadership Update from Christy Wyskiel

Please join me in celebrating two exciting leadership changes at JHTV. Steve Kousouris, who has been serving as Interim Executive Director of Technology Transfer at JHTV since June, has assumed this role permanently effective Jan.1. Additionally, Mark Bailey, previously Associate Director of Finance, will assume responsibility for the portfolio that Steve has overseen since 2013 in the capacity of Director, Finance & Administration.

World’s Top 50 Universities For Computer Science Degrees, 2019 – Johns Hopkins and University of Maryland listed

MOVE over Caltech, Georgia Tech, and MIT – the University of Oxford has been named the best university in the world for computer science degrees for 2019. The ranking compares the top computer science programs in the world. ETH Zurich ranked number 2 on the list, followed by Stanford University (No. 3), the University of Cambridge (No. 4), and Massachusetts Institute of Technology (No. 5).

FDA plans to create a new office to leverage cutting-edge science – STAT

The Food and Drug Administration plans to create a new office to improve the review of new medicines — one that will develop a standardized approach to using personalized medicine, digital data, and patients’ own reports, according to Commissioner Scott Gottlieb.

Top 10 Global Biopharma IPOs of 2018

2018 was a record year for biopharma initial public offerings (IPOs), with an all-time high of $6.3 billion raised by 58 U.S. companies as of December 17, according to Renaissance Capital, compared with 36 companies garnering some $4 billion in 2017.

Why pharma is starting to think more like Amazon – MedCity News

Pharmaceutical companies are starting to see the retail supply chain as more than just a way to get drugs from point A to point B. It can be an opportunity to ensure better products and services and create a competitive advantage with consumers – but only if data is connected and well managed.

Baltimore’s b.well Connected Health honored as ‘Top Innovator’ at Accenture’s global health startup competition – Technical.ly Baltimore

A pair of Baltimore-based digital health startups were among the award winners at the conclusion of the Accenture HealthTech Innovation Challenge this week.

Precision medicine is “not at loggerheads” with population health – MedCity News

Precision medicine is using knowledge about a person’s genetic code to tailor treatments to that individual for the most optimal outcome. Think of sequencing tumors and then determining a treatment regimen based on biomarkers or genetic variants.

2018 New Drugs Approvals: An All-Time Record, And A Watershed

For months, it had been clear that 2018 would be a banner year for pharmaceutical innovation. The question was, by how much would it shatter the previous (1996) record of 50 approvals (excluding diagnostics and imaging agents)? We now know. It exceeded it by over 20 percent. Last year, U.S. regulators approved a total of 61 drugs – 59 by FDA’s Center for Drug Evaluation and Research (CDER), plus two recombinant therapies (Andexxa and Jivi) by its Center for Biologics Evaluation and Research (CBER).

NJBIA Releases Indicators of Innovation Report – Insider NJ

Indicators of Innovation, a report issued today by the New Jersey Business & Industry Association, shows New Jersey at a challenging crossroads in its efforts to reclaim itself as the “Innovation State.”

JPMorgan Conference Is So Packed Attendees Meet in the Bathroom – Bloomberg

Brianna Wronko has an engineering degree from an Ivy League school and is the CEO of a health-care diagnostics company. Until this week, she never thought she’d be stuck holding business meetings in a San Francisco hotel bathroom.

Jan 28 2019

Love0

336th Edition – January 10, 2019

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

January 10, 2019

FOUNDING MEMBER OF

Emergent BioSolutions Announces Daniel J. Abdun-Nabi to Retire as CEO; Robert G. Kramer, Sr. to Become President and CEO | Seeking Alpha

Many thanks to Dan for his leadership of Emergent, his service as a loyal BHI Board Member, and for helping to accelerate the growth of the BioHealth Capital Region.

Emergent BioSolutions Inc. (EBS) today announced that its CEO Daniel J. Abdun-Nabi will be retiring and that its board of directors has unanimously appointed Robert G. Kramer, Sr., the company’s current president and COO, to succeed him as president and CEO, effective April 1, 2019. Mr. Abdun-Nabi has also indicated that he plans to step down as a member of the Emergent board of directors, and Emergent expects the board of directors to appoint Mr. Kramer to fill the board vacancy created by Mr. Abdun-Nabi’s retirement.

Scoop: MedImmune chief Bahija Jallal is leaving AstraZeneca and joining the trek into biotech – Endpoints News

Congratulations to Bahija on making MedImmune the leading BioHealth company in Maryland and accelerating its growth. Also many thanks for MedImmune’s longtime support of BHI and for helping the BioHealth Capital Region become the 4th largest Biopharma Cluster in the country.

Six years after AstraZeneca’s then new CEO Pascal Soriot named Bahija Jallal president of the big MedImmune subsidiary in Gaithersburg, MD, putting her at the center of the company’s R&D turnaround plans, the longtime pharma exec is joining the great migration of industry professionals to biotech.

Pasadena’s Alexandria Venture Investments Recognized as #1 Most Active Investor in Healthcare Startups

Congrats to Alexandria a BHI partner and Board Member for their commitment to early-stage BioHealth investing.

Alexandria Venture Investments, the strategic venture capital arm of Alexandria Real Estate Equities, Inc. based in Pasadena, was recognized by Silicon Valley Bank as the most active biopharma investor by new deal volume in 2017-2018.

The University of Maryland Robert E. Fischell Institute for Biomedical Devices Celebrates its Official Launch

The University of Maryland Robert E. Fischell Institute for Biomedical Devices celebrated its official launch on Thursday, January 3, 2019. The event included presentations by researchers at the Institute and supported by the the Institute taking place at the A. James Clark School of Engineering, the University of Maryland School of Medicine, Children’s National Health Center, University of Maryland Insitute for Bioscience and Biotechnology Research.

The 20 Top Universities In The United States For 2019 – Congrats to John Hopkins

What are the top universities in the United States? The list is decided by the CEOWORLD magazine university ranking which considers 7 important factors to help make a balanced comparison. These include influence, reputation, specialization, recruiters Responses and employers Feedback, which in turn help to rate and rank the top unis.

Why Rockville – BioHealth Innovation

Why Rockville Video, produced by Rockville Economic Development, Inc., featuring BioHealth Innovation’s Judy Costello.

BrainScope Receives FDA Clearance for Multi-Modal, Multi-Parameter Concussion Assessment — BrainScope

BrainScope Receives FDA Clearance for Multi-Modal, Multi-Parameter Concussion Assessment

New Concussion-Specific FDA Labeling Adds to Existing BrainScope Claims Complements Multi-Modal Technology Platform and Extensive Intellectual Property Portfolio To Address New Brain and Behavioral Health Conditions

PGDx signs a pair of partnerships as it looks to expand ‘kitted’ cancer tests – Technical.ly Baltimore

Personal Genome Diagnostics is starting off the year with news of a pair of partnership agreements as it looks to expand its approach to cancer testing.

Top University of Maryland School of Medicine Genomics Scientist Claire M. Fraser, Phd, Appointed President-Elect of American Association for the Advancement of Science (Aaas)

University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today that Claire M. Fraser, PhD, a pioneer in the field of microbialgenomics, who is the Dean’s Endowed Professor, Department of Medicine, and Director of the Institutefor Genome Sciences (IGS), has been chosen as president-elect of the American Association for the Advancement of Science (AAAS). AAAS is the world’s largest multidisciplinary scientific society and a leading publisher of cutting edge research through its Science family of journals.

AGT Newsletter Volume 7

In wrapping up the year, AGT was proud to be featured as a State of Maryland “Success Story” for its growth in Maryland and achievements in the gene and cell therapy industry.

Tax Implications & Accounting Issues for Start-ups – PathFinder Innovation Program

Wednesday, January 23, 2019, 12:00 – 4:00pm

Are you a young company or thinking of starting up a new firm. What do you need to know related to taxes? –tax credits? Filing? Tax liability? Other accounting issues? Learn the answers to these questions and more.

12:00 p.m. – Networking Lunch
12:30-1:30 p.m. – Panel and Q&A with experts
1:30 p.m. – 1:1 meetings*

*Attendance at Panel is required to participate in 1:1 meeting with expert.

**In person at BHI HQ, 1 Church Street, Rockville, MD or by videoconference.

Md. ranks among best for tech economy – Maryland Daily Record

Maryland placed third on think tank Milken Institute’s 2018 State Technology and Science Index, ranking innovation pipelines. Maryland also placed third in 2016’s report.

Useful Stats: NIH SBIR/STTR Success Rates by State (2008-2017) | SSTI

Here is a significant opportunity for MARYLAND to grow in SBIR success.

One of the best ways to measure the effectiveness of state programs intended to encourage the success of SBIR applications is the approval-rate of their submissions. Although this data has been historically unavailable across every federal agency, it is now accessible for the National Institutes of Health (NIH), the second largest provider of SBIR/STTR awards, according to a 2018 Digest report. The NIH distributed $446.2 million in SBIR/STTR awards in 2017, with every state except North and South Dakota receiving an award. Although California and Massachusetts had the most successful SBIR/STTR applications in 2017, accounting for roughly one-third of the total when combined, neither state ranked among the top 10 in success rate.

J.P. Morgan healthcare conference topics January 7

Now in its 37th year, the conference has ballooned from a small event with 150 attendees that was essentially the ” birth of biotech,” to an event attended by everyone from the biggest pharma company to the smallest biotech. JPMorgan said more than 485 companies are scheduled to present this year.

Maryland Life Sciences Breakfast – Maryland’s Advancements in Vaccines and Immunotherapeutics Event Registration | Maryland Tech Council

Tuesday, January 15, 2019 8:30AM – 10:30AM

GSK 9911 Belward Campus Drive Rockville, MD 20850

The Maryland Life Sciences, a division of the Maryland Tech Council, brings together vaccine leaders to discuss current breakthroughs in the world of vaccines and immunotherapeutics. This breakfast meeting will address innovating strategies to meet current health threats, changing technology for vaccine manufacturing and provide a snapshot of where vaccine development stands today.

Join us for breakfast, networking and a discussion to hear about the experiences and insights on the current state and projected future of treatments. Local leaders will also discuss challenges and opportunities that come with vaccine and immunotherapy development used by companies in our State.

The most educated town in every state – Business Insider

Different places have different levels of educational achievement.

The American Community Survey is an annual survey run by the Census Bureau to allow the government, corporate and academic researchers, and anyone who is curious about demographics to better understand the US population. Among many other subjects, the ACS includes questions about respondents’ education levels.

GAO: Agencies aren’t tapping venture capital-owned companies for innovation

Though federal agencies are hungry for new technology solutions, a report from the Government Accountability Office says they may be missing out on a key avenue of innovation.

5 Biopharma Trends to Watch in 2019 | GEN – Genetic Engineering and Biotechnology News

“If you can look into the seeds of time, and say which grain will grow and which will not, speak then unto me,” Banquo beseeches the witches in Shakespeare’s “Macbeth,” seeking insight into the future for himself and his closest friend Macbeth.

Key Life Science Industry Trends in 2019

The Pistoia Alliance announced key trends for the life science industry in 2019 based on The Life Sciences Innovation Report developed with Clarivate Analytics.

State Technology and Science Index 2018

The STSI’s 107 individual indicators are sorted into five composites: research and development (R&D) inputs, risk capital and entrepreneurial infrastructure, human capital investment, technology and science workforce, and technology concentration and dynamism.

Industry execs forecast the year ahead for gene therapy at Biotech Showcase – MedCity News

The first Food and Drug Administration approvals for cell and gene therapies are already more than a year out, but 2019 is likely to be a significant year for the field, particularly in areas like international interest, industry consolidation and pricing. That was the theme of a panel discussion Monday morning at Biotech Showcase in San Francisco, which coincides with the 2019 J.P. Morgan Healthcare Conference.

Top 20 Life Science Startups to Watch in 2019 | BioSpace

BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.

Biggest Pharma M&A Ever Propels Bristol to Cancer Lead – Bloomberg

Bristol-Myers Squibb Co.’s $74 billion planned purchase of Celgene Corp. puts it in line to lead the drug industry’s hottest market, cancer, as early as next year.

Atlas Venture raises $250M for Opportunity Fund – MedCity News

A biotechnology venture capital firm is ringing in the new year with its latest fund, having raised a quarter of $1 billion.

Cambridge, Massachusetts-based Atlas Venture said Wednesday that it closed its first Opportunity Fund, or AVOF I, with an oversubscribed fund raise of $250 million. The firm plans to invest the money in companies already in its portfolio.

Four payer market predictions for 2019 – MedCity News

Having analyzed the trends and the shifting winds in the payer marketplace, it’s time to gaze into the crystal ball and see what the future has in store.

Jan 28 2019

Love0

335th Edition – Year in Review – January 4, 2019

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

January 4, 2019

BHI News Year in Review

Below are BioHealth Innovation News’ most popular articles from 2018:

Army Doctors Grew a Soldier a New Ear — On Her Forearm – Time

May 14, 2018

You’ve heard the cliché about wearing your heart on your sleeve. But a group of Army doctors did one better: They grew a new ear on a soldier’s forearm, using cartilage harvested from her ribs.

Think Resources: BioHealth Innovation – Rich Bendis interview with MCEDC

January 20, 2018

MCEDC talks with Rich Bendis, President and CEO of BioHealth Innovation, about how his organization fuels the science industry in Montgomery County, Maryland.

BHI CEO Rich Bendis’ Opening Presentation at The 2018 BioHeath Capital Region Forum

April 25, 2018

Welcome to the 2018 BioHealth Capital Region Forum: State of the BioHealth Capital Region’s EcoSystem

Presented by: Rich Bendis, President & CEO, BioHealth Innovation Inc.

BioHealth Innovation Appoints Jarrod Borkat as new Vice Chairman of the Board

May 22, 2018

MedImmune Sr. Director, Partnering & Strategy filling role previously held by Emergent BioSolutions CEO, Daniel J. Abdun-Nabi

BioHealth Innovation, Inc. (BHI) announced that its Board of Directors has unanimously approved the appointment of MedImmune Sr. Director, Partnering & Strategy, Jarrod Borkat as new Vice Chairman. MedImmune, the global biologics research and development arm of AstraZeneca, is a Founding Partner of BHI and continues to be a leader in building the BioHealth Capital Region. BHI would like to thank Emergent BioSolutions CEO, Daniel J. Abdun-Nabi, for his service as Vice Chairman. He will remain as a member of the Board of Directors. Mr. Abdun-Nabi also previously served as chairman of the Maryland Life Sciences Advisory Board (LSAB) and currently serves on Maryland Governor Larry Hogan’s Excel Board.

Galen Robotics Wins BioHealth Capital Region 3rd Annual Crab Trap Competition

April 26, 2018

Competition held during 2018 BioHealth Capital Region Forum

Wilson Sonsini’s Charlie Andres and BHI’s Rich Bendis present the team from Galen Robotics their award for winning the 2018 Crab Trap competition

ROCKVILLE, MARYLAND, April 26, 2018 – Galen Robotics, a Johns Hopkins University spinout, was chosen from five finalists as the company with the most commercial potential by judges at the 3rd Annual Crab Trap Competition. This year’s judges included industry leaders Amgen’s Bethany Mancilla, AstraZeneca’s Shaun Grady, Blu Venture’s Dr. Paul Silber, J.P. Morgan’s John T. Rubin, New Enterprise Associates’ Sara Nayeem, Roche’s Robert Silverman, and Sands Capital Ventures’ Stephen Zachary. They were impressed with a presentation by Lead Hardware Engineer, Yunus Sevimli, on Galen Robotics’ low-cost, compact, and intuitive to use novel microsurgical robotic platform designed to assist surgeons with minimally-invasive applications in otolaryngology, neurosurgery and similar critical fields. Galen Robotics is the third Johns Hopkins University spinout to win this competition following LifeSprout (2017) and Sonavex (2016).

Strong presentations also were made by the other finalists–AlgometRx, Cellth Systems, Renalert, and Reveragen Biopharma—whose technologies originated at Children’s National Medical Center, the University of Maryland, and Johns Hopkins University.

Montgomery County, Maryland-based BeneVir Biopharm, Inc. to be acquired by Janssen Biotech, Inc. for up to $1.04B

May 7, 2018

Company’s announcement latest in recent trend of significant investment in Montgomery County biohealth companies.

BeneVir Biopharm, Inc. (BeneVir), a privately-held Montgomery County biotech company, has entered into an agreement under which it will be acquired by Janssen Biotech, Inc., a Johnson & Johnson company for up to $1.04 billion. Under the terms of the agreement, Janssen will make an upfront cash payment of $140 million at closing of the transaction, plus additional contingent payments of up to $900 million based on achievement of certain predetermined milestones. BeneVir was a client of BioHealth Innovation (BHI) from 2013 until its Series A investment in 2014.

BioHealth Innovation Receives InBIA January IMPACT Award

March 6, 2018

BioHealth Innovation, Inc. (BHI) has received the International Business Innovation Association (InBIA)’s January 2018 IMPACT Award in Biotech/Cleantech for the management of four spaces for early stage companies: the Germantown Innovation Center, the Rockville Innovation Center, LaunchLabs, and the BHI International Innovation Center. The award is based on a variety of metrics including affiliations and partnerships, application and graduation, facilities, mission and goals. This recognition also enables this innovation activity to be considered with other leading entrepreneurial centers across the country as a finalist for the InBIA’s annual Incubator of the Year Awards.

Maryland Biotechs Dominate 2018 Vaccine Industry Excellence Awards – BioBuzz

April 23, 2018

More than a dozen biotech companies or researchers from the Maryland biotech cluster, which some have also dubbed ‘Vaccine Alley’, were among the most recognized finalists at this year’s Vaccine Industry Excellence (ViE) Awards in Washington, DC at the World Vaccine Conference. In fact, 15 out of the 54 finalists, or 27%. were from right here in Maryland. This year’s conference was held in Washington, DC so could this have been a case of home court advantage? Probably not. More than likely it’s because this region holds 20% of the top influencers worldwide in vaccine development.

Supernus Pharmaceuticals to acquire Biscayne Neurotherapeutics for up to $185M – Washington Business Journal

September 17, 2018

Rockville-based Supernus Pharmaceuticals Inc. has reached a deal to acquire Miami-based Biscayne Neurotherapeutics in a deal worth up to $185 million.

BioHealth Capital Region Industry Compensation Survey™

April 25, 2018

Is your employee compensation package competitive?

Help us help you. Complete the 2018 BHCR Industry Compensation Survey by June 1, 2018 to receive an anonymized summary of salaries and benefits specific to positions in biohealth and to this region. A pdf version of the survey is available here or you can use the online version of the survey to complete your information. All company specific information will be kept confidential. This survey is a joint project among BioHealth Innovation, WorkSource Montgomery, and UMBC-Shady Grove’s Industrial Organizational Pyschology Program. If you or your Human Resources colleagues have any questions about the survey, please contact BHI@BioHealthInnovation.org.

Biomaterials Could Extend the Success of Immunotherapies – GEN

January 8, 2018

The use of biomaterials, such as microneedles and nanoparticles, in immunotherapy and vaccine research is a hot topic in bioengineering. But to get the maximum return on investment in these ideas, they need to be seeded among clinicians, according to Christopher Jewell, Ph.D., associate professor in the Fischell Department of Bioengineering at the University of Maryland. Jewell is the principal author on a new paper in Trends in Immunology that reviews the current state of biomaterials research with an eye toward inspiring multidisciplinary teams of engineers and clinicians to solve some of the complex problems in immunology today.

China-based pharma firm KBP Biosciences plans HQ move to Philly area

January 8, 2018

A drug development company has raised $76 million from investors in China, the United States, and Korea to move its headquarters to the Philadelphia area from Jinan, China, and bring treatments developed by China-based scientists through U.S. clinical testing to patients here.

TaiRx, Inc. and BioHealth Innovation, Inc. Form TaiRx US to Develop and Commercialize Therapeutics and Precision Medicine Diagnostics

October 22, 2018

TaiRx, Inc and BioHealth Innovation, Inc. (BHI) announced today the formation of TaiRx US, a new joint venture. The mission of the new company is to develop therapeutics and precision medicine diagnostics focused on the Nodal protein, a critical mediator of aggressive cancer progression and treatment resistance.

TaiRx, Inc and BHI have formed TaiRx US, which will be based in Rockville (Montgomery County), Maryland, to develop and commercialize a unique monoclonal antibody with the potential to reverse drug resistance in various tumor types. The company is also working to develop a companion diagnostic to accurately identify those patients who can best benefit from the therapy.

PepVax Announces Completion of Efficacy Study with Key Pre-Clinical Data to Validate PVX-009,

January 13, 2018

PepVax, Inc., an early-stage biotechnology company, announced today that it has successfully completed the efficacy study for its lead candidate, PVX-009. The Company is harnessing the power of the immune system to target a specific protein, MAGE A, in an effort to find a treatment for triple negative breast cancer (TNBC).

Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax

August 13, 2018

Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to acquire PaxVax, a company focused on specialty vaccines that protect against existing and emerging infectious diseases, for an all-cash consideration of $270 million. PaxVax is majority owned by an affiliate of Cerberus Capital Management, L.P.

Six pediatric device innovators awarded total of $150K at Children’s National 6th Annual Pediatric Device Symposium

September 25, 2018

A total of $150K was awarded to six pediatric cardiovascular innovations during the medical device pitch competition at the 6th Annual Pediatric Device Innovation Symposium hosted by Children’s National Health System. Award winners with Children’s National Vice President Kolaleh Eskandanian (far left) and CEO Kurt Newman, MD, (far right) include: Ken Nelson, Bardy Diagnostics; Henri Justino, MD, PolyVascular Corp.; Corin Williams, Draper; Doug Vincent, VentriFlo; Joshua Woolley, NuPulseCV; and Kurt Newman, MD, Children’s National Health System. Peca Labs, not pictured, was also an award recipient. Photo credit: Paul Loftland Photograph

Six companies presenting innovative medical devices that address significant unmet needs in pediatric healthcare were awarded a total of $150,000 in grants yesterday in Philadelphia, Penn.at the Sixth Annual Pediatric Device Innovation Symposiumorganized by the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children’s National Health System.

The “Make Your Medical Device Pitch for Kids!” competition this year focused on pediatric cardiovascular devices, an area where new devices can make a life-changing difference, especially for younger children. The Centers for Disease Control and Prevention estimate that 40,000 children are born annually in the U.S. with a congenital heart defect (CHD) and approximately 1 million U.S. children currently live with a CHD.

The pitch competition was originally slated to award $100,000 in grants; however, because of the judges’ response to the quality and potential of the technologies presented, Children’s National expanded the award grants to $150,000 to include six awardees.

Altimmune Appoints Mitchel Sayare as Executive Chairman of the Board, and Adds José Ochoa to Its Leadership Team as Chief Business Officer – NASDAQ.com

July 16, 2018

Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company focused on infectious disease, today announced it has appointed Mitchel Sayare, Ph.D., as Executive Chairman of the Board, effective immediately.

What’s next for biotech? – Innovators magazine

January 29, 2018

Innovators Magazine asked some biotech stakeholders what trends they expect to see in their markets this year.

The opinions were published in our special biotechnology edition, which was distributed to delegates at an industry conference in Glasgow this week.

Biohealth Capital Region aiming for top 3 status – Smart Incentives

April 30, 2018

The Biohealth Capital Region–DC, Maryland and Virginia – plans to be a top 3 biohealth hub in the US by 2023. What will it take to get there?

The Biohealth Capital Region is already a top 5 location as ranked by NIH and venture capital funding, patents, lab space, and jobs. The 1,100 participants at this week’s 2018 Biohealth Capital Region Forum agreed on the area’s strengths: a highly educated and diverse workforce, leading universities and research institutions, strong healthcare organizations, hundreds of companies, and broad-based policy commitment to the biohealth industry.

Novavax Appoints Rachel King to Board of Directors – NASDAQ.com

November 5, 2018

Novavax, Inc., (Nasdaq:NVAX) today announced the appointment of Rachel King, Co-Founder and Chief Executive Officer of GlycoMimetics, Inc., to its Board of Directors. In addition to extensive experience as an executive in the biotechnology industry, Mrs. King has also worked in the venture capital side of life sciences, and has held executive positions within a global multinational pharmaceutical company.

Baltimore medical device startup Perceptive Navigation LLC looks to raise $4 million – Baltimore Business Journal

March 20, 2018

Baltimore medical device firm Perceptive Navigation LLC is looking to raise $4 million in new funding, according to a recent filing with the U.S. Securities and Exchange Commission.

Solera Health and WellDoc Partner to Offer Health Plans and Employers a Holistic Approach to Diabetes Prevention and ManagementSolera Health will integrate the BlueStar® Digital Therapeutic, a… | Markets Insider

January 20, 2018

Solera Health, an integrated benefit network, and WellDoc®, a leading digital therapeutic company, announced today that WellDoc’s BlueStar® digital therapeutic will join the Solera network as a diabetes management solution of choice. The partnership aligns both companies’ goals to improve the lives of those living with chronic diseases while enhancing clinical results and decreasing overall healthcare costs.

Montgomery County Council provides $425,000 for fiscal year 2019 operating budget to fund Small Business Innovation Research Matching Grant Program – First County in the US to offer a SBIR matching grant program

May 29, 2018

The Montgomery County Council approved the fiscal year (FY) 2019 operating budget on Thursday, May 24, 2018. Included in the budget is a total of $425,000 for the Small Business Innovation Research (SBIR) Matching Grant Program. The program provides matching fund for businesses that receive federal SBIR and Small Business Technology Transfer (STTR) grants.

Bill 41-17, Economic Development Fund – Small Business Innovation Research and Small Business Technology Transfer Matching Grant Program established a County matching fund for businesses that receive federal SBIR and STTR grants. Councilmember George Leventhal, who serves as chair of the Council’s Health and Human Services Committee and is a member of the Planning, Housing and Economic Development Committee, was the lead sponsor of Bill 41-17. All other Councilmembers were cosponsors.

Maryland in Top 10 States that Added Jobs (Virginia and DC in Top 30) – Governing.com

January 30, 2018

Nearly all states added jobs in 2017, but the latest Labor Department data suggests most states experienced slower growth last year than in 2016.

Still, it proved to be a particularly strong year for a select group of states — 10 of which recorded year-over-year job gains exceeding 2 percent.

All Eyes on Better Health at CES 2018: Innovation Awards Honoree RightEye Debuts EyeQ System | Business Wire

January 9, 2018

RightEye LLC, an award-winning technology innovator using eye tracking to revolutionize patient care and vision performance, announced today it will be debuting its new RightEye EyeQ system tonight at CES Unveiled Las Vegas at 5:00 p.m. at the Mandalay Bay Shorelines Exhibit Hall in Las Vegas, Nevada. EyeQ gives people a closer look at their health using quick, computer game-style vision tests on an eye-tracking computer. The tests, which only take a few minutes, generate an instant EyeQ Report that provides results in an easy-to-understand format to support discussion with doctors on diagnosis and recommended therapies.

Press release – KeyGene Licenses University of Wisconsin Sequence-Based Genotyping Patents – Keygene

January 16, 2018

KeyGene and the University of Wisconsin-Madison announced today that they have entered into a service license agreement to practice KeyGene’s patented Sequence Based Genotyping (SBG) methods. Under the agreement, UW-Madison, through its Biotechnology Center (UWBC), is licensed to offer SBG services in all species to research collaborators and clients worldwide.

BIO 2018 Recap

June 19, 2018

Business partnering, education and networking was the focus of 3500 biohealth industry leaders who attended the BIO International Convention (BIO) Conference earlier this month in Boston. At the event, BIO set the GUINNESS WORLD RECORDS title for the Largest Business Partnering Event with 41,400 partnering meetings. Many of these meetings took place in the pavilion hosted by the Maryland Department of Commerce which included space for meetings BioHealth Innovation, Montgomery County Economic Development Corp (MCEDC), Rockville Economic Development (REDI), the City of Gaithersburg, Viva White Oak, PIC-MC (Montgomery College), University of Maryland Ventures, Johns Hopkins University, Fina BioSolutions, Integrated Pharma Services, Pharmaceuticals International, Inc., Emergent BioSolutions, AsclepiX, and US FDA’s Tech Transfer Office. Others from the BioHealth Capital Region who attended included: ABL, American Gene Technologies, AstraZeneca / MedImmune, Altimmune, BioMarker Strategies, Bytegrid, Children’s National Health, CRBE, Creatv Microtech, GlycoMimetics, IDT Biologica, Immunomics, Intrexon, Leidos Health, MacroGenics, Maryland Tech Council, MaxCyte, Newport Board Group, Novodux Paragon Bioservices, REGENXBIO, MacroGenics, Neuronascent, Scheer Partners, Smithers Avanza, TEDCO, the University of Maryland Baltimore, and the University of Maryland’s Institute of Bioscience and Biotechnology Research.

Lupin receives FDA approval for generic Tamiflu Capsules

January 16, 2018

Pharma Major Lupin announced that it has received final approval for its Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base), and 75 mg (base) from the United States Food and Drug Administration (FDA) to market a generic version of Hoffman-La Roche, Inc.’s Tamiflu Capsules, 30 mg, 45 mg, and 75 mg.

Protenus plans Baltimore hiring push after raising $11M Series B – Technical.ly Baltimore

January 22, 2018

Six months after closing its most recent funding, Protenus reported raising $11 million in Series B funding, and is planning more hiring.

TEDCO adds five companies to seed portfolio with $600,000 in new investments – Baltimore Business Journal

February 6, 2018

Maryland Technology Development Corp. made new seed investments in five Maryland startup companies, totaling $600,000.

TEDCO has invested hundreds of thousands of dollars in young, growing companies across the state. The state-backed organization has 137 active investments through its seed fund.

AgriMetis Opens New Lab in Gaithersburg, Maryland — AgriMetis

AgriMetis, LLC is pleased to announce the opening of its new laboratory in Gaithersburg, Maryland. The new laboratory is located at 401 Professional Drive, which is in the heart of the Maryland Biotech region along the I-270 corridor.

Why Roche’s $1.9 Billion Deal to Buy Flatiron Health Matters – Fortune

February 19, 2018

The big headline out of the health care M&A world today is Swiss pharmaceutical giant Roche’s $1.9 billion acquisition of Flatiron Health, the Alphabet-backed, cancer-focused digital health analytics upstart that’s attempting to use real world patient information and big data to spur better oncology R&D.

Startup with Johns Hopkins roots raising $40.5 million to develop cancer metabolism drugs – Endpoints News

February 5, 2018

A new oncology company spun out of Johns Hopkins School of Medicine is raising up to $40.5 million to develop its platform of anticancer therapies.

Qiagen Gets FDA OK for Expanded Use of EGFR CDx for Lung Cancer Drug – GenomeWeb

January 22, 2018

Qiagen said today that the US Food and Drug Administration has extended the indications for use of its Therascreen EGFR RGQ PCR kit to guide the use of Boehringer Ingelheim’s Gilotrif (afatanib) for first-line treatment of patients with metastatic non-small cell lung cancer harboring non-resistant EGFR mutations.

Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results

March 12, 2018

Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced financial results for the year ended December 31, 2017.

Machfu Announces Release of MACH-3 Industrial Internet of Things Platform and Gateway | Business Wire

January 15, 2018

Machfu, an Industrial Internet of Things (IIoT) technology company, announced today the release of its MACH-3 IIoT Gateway, a device allowing companies in energy, water, oil and gas as well as other industrial segments to seamlessly connect legacy infrastructure to cloud based IoT and existing SCADA systems. The product was designed to both simplify the connection and management of devices as well as provide a secure and easily customizable application framework to process and manage data at the network edge. The versatile functionalities of the MACH-3 IIoT Gateway will be demonstrated at the 2018 DistribuTECH show, January 22-25 in San Antonio, Texas.

Top 50 NIH-Funded Institutions of 2018 | The Lists | GEN

June 4, 2018

The National Institutes of Health (NIH) invests nearly $37.3 billion annually in medical research. More than 80% of the funding is awarded through nearly 50,000 competitive grants to more than 300,000 researchers at more than 2500 universities, medical schools, and other research institutions in every U.S. state and around the world.

Innovation for Impact Prize – SoBran, Inc.

February 27, 2018

Tell us about the impact your research may make on the world. You could win a free pre-clinical research study valued up to $20,000 and $1,000 in cash, or additional cash prizes.

SoBran and the Maryland Tech Council are celebrating the transformational science coming out of the Maryland and surrounding area by establishing the Innovation for Impact Prize.

Dec 18 2018

Love0

334th Edition – December 18, 2018

By admin BHI Weekly Newsletter Archives

BioHealth Innovation

If you are having trouble viewing this email, please click here

December 18, 2018

FOUNDING MEMBER OF

VLP Therapeutics Awarded $3.9 million Grant by Global Health Innovative Technology Fund for Further Development of Dengue Vaccine

The Global Health Innovative Technology (GHIT) Fund has awarded VLP Therapeutics a $3.9 million grant to further develop a novel tetravalent dengue virus-like particle vaccine.

Camden Partners Nexus co-leads $3.7M investment in pharmaceutical company treating hearing loss – Technical.ly Baltimore

Early-stage pharmaceutical company Spiral Therapeutics received $3.7 million in new investment as it looks to advance treatments for hearing loss and other inner ear disorders.

The Gene Therapy Market is going to produce a Microsoft – American Gene Technology

The most common analogy used to compare the science of DNA to other industries is that of computer software. DNA can be viewed as a series of commands (genes) that are coded in four nucleotides (represented by A, G, C, and T). Those letters are interpreted by the cellular machinery to produce cell products like enzymes, proteins, and various building blocks of the cell itself. This code somewhat parallels the “machine language” of computers. Computer’s lists of commands (coded in zeros and ones) are interpreted to work with numbers or any type of information that is converted to numbers (like audio, video, or sensor data). Resulting numbers generate numerical output for machinery such as screen displays, motors, tools, robots, digital controls, etc.

Eversense CGM Wins a 2018 “Best of What’s New” Award – Senseonics

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today has announced that the Eversense® Continuous Glucose Monitoring (CGM) System has been awarded one of Popular Science’s 2018 “Best of What’s New” Awards in the Health category.

EDUCATIONAL & SCIENTIFIC, LLC AND UNIVERSITY OF MARYLAND, BALTIMORE EXPAND RELATIONSHIP THROUGH LICENSING AGREEMENT TO DEVELOP NOVEL PROSTATE CANCER TREATMENT

University of Maryland (UM) Ventures and Educational & Scientific, LLC (ESL) announced today that the University of Maryland, Baltimore (UMB) has again granted ESL an exclusive license for a novel cancer treatment. This agreement focuses on the development of Galeterone, a molecule with the potential to inhibit prostate cancer growth in patients with castration-resistant prostate cancer (CRPC). Galeterone is a steroidal antiandrogen that acts by disrupting the androgen receptor signaling pathway, which is the primary pathway that drives prostate cancer growth.

Maryland Stem Cell Research Consortium Funding Opportunities – Deadline 1/17/19

The Maryland Stem Cell Research Fund provides a variety of grant programs for human stem cell research in the state of Maryland. Each RFA has its own timeline and review process; please read carefully the RFA when applying.

2018 In Review with MIMETAS’ CEOs

2018 was a year in which we saw explosive growth at Mimetas. After such a hectic and promising year, it is important to take a moment to sit down and recap some of the highlights. Today, we sit down with our CEOs, Jos and Paul. In this conversation, you will read their thoughts about the Mimetas culture, corporate dynamics, amazing new products, and the strengths they perceive in each other.

BullFrog AI Announces New Chief Technology Officer – BullFrog AI

BullFrog AI, Inc, a precision pharmaceutical company built around a powerful artificial intelligence (AI) platform, proudly announces the addition of executive Everett Lee as its Chief Technology Officer. Mr. Lee brings nearly 3 decades of technical expertise and continuous advancement in technology management, strategic business planning and IT organizational leadership at major pharmaceutical/biotech and drug development companies such as AstraZeneca, Roche/Genentech, Eli Lilly & Co., Pfizer and Covance.

Growing our Understanding of Nanotech

Intelligent nanobots offer the promise of smart drug delivery systems for a variety of therapeutic applications. A promise that experts in the field believe will become a reality within the next 30-40 years.

But at MedImmune, we don’t think patients should have to wait.

39 years and counting: Johns Hopkins again leads country in R&D spending – Baltimore Business Journal

A large chunk of the school’s research spending — about $1.5 billion — can be attributed to Hopkins’ Applied Physics Laboratory, based in Laurel.

Draft ROI Report is a Promising Roadmap for Accelerating Tech Transfer

After months of anticipation, the just released draft paper Return on Investment Initiative to Advance the President’s Management Agenda: Unleashing American Innovation signals that the Administration is serious about addressing a wide range of long neglected issues undermining effective technology commercialization. The paper, generated under the leadership of Commerce Under Secretary Walter Copan, who heads the National Institute of Standards and Technology (NIST), is “a discussion document” based on feedback from a series of public meetings and written comments for improving the return on investment from $150 B spent annually on government-supported R&D.

Frederick National Laboratory, Frederick Innovative Technology Center Inc. partner for accelerator – fredericknewspost.com

The Frederick National Laboratory for Cancer Research and the Frederick Innovative Technology Center Inc. signed a memorandum of understanding with partners Monday to start an accelerator program for biotechnical companies.

JLABS: This Incubator Knows How to Get Biotech Companies Started

When it comes to drug discovery and development, nowadays a lot of the work is done by small- or medium-sized healthcare companies. The biopharma industry heavily relies on their results, so SMEs carry an immense load on their shoulders. But without outside help, their mission is nearly impossible.

Go inside Alexandria’s LaunchLabs incubator in Kendall Square – Boston Business Journal

The former Belly Wine Bar and The Blue Room in Cambridge’s Kendall Square has been transformed into a biotech incubator.

The Value of Bioscience Innovation in Growing Jobs and Improving Quality of Life 2018 – BIO

This eighth, biennial report focuses on the economic progress and footprint of the industry geographically including the performance, positioning and latest trends in the bioscience industry for the nation, states and metropolitan areas. For the first time, it includes a national assessment of the full economic impact of the bioscience industry not only in terms of employment, but also with respect to economic output and fiscal impacts. In addition, the report details the nation’s academic research activities and trends in federal funding, access to critical angel and venture capital and the innovation outputs context via patent activities.

Top 10 Molecular Millionaires of 2018

The last time GEN compiled a list of CEOs, investors, and others with the biggest stakes in biopharma companies—what GEN calls “molecular millionaires”—was last year, based on 2016 data. Only one new person who had not been listed in previous editions made the cut back then.

Four Tips For Raising Venture Capital In The Biotechnology Sector

In a world where it seems like startups are created every other day and market economics remain largely unpredictable, securing funding for your biotech startup can prove to be an arduous task. Venture capitalists prefer tested and proven biotech enterprises, government- and NGO-backed funding remain ever so slightly out of reach, and every other funding outlet seemingly comes with its own set of hard-to-match requirements and specifications. What is the fate of the budding startup without experience in the harsh economic climate of today’s biotech ecosphere? As it turns out, it’s not quite as bad as one would expect. It’s all down to knowing the ropes and peculiarities of the market.

Why do digital health startups keep failing?

A decade ago, a wave of companies promised to transform people’s health by allowing them to track data about their eating, sleep, exercise, and other habits. One hot startup of that moment, Zeo, raised more than $30 million from investors to develop a headband that tracked users’ sleep patterns and an accompanying app to serve as their personal “sleep coach.” Despite devoted users and buzz about its product in publications like Wired and Popular Science, Zeo quietly went out of business a few years later.

Is a cancer vaccine on the horizon? – Science Focus – BBC Focus Magazine

The idea of using patients’ own immune cells to fight cancer is over a hundred years old. In the late 19th century, an American doctor called William Coley attempted to treat cancer by stimulating the immune system with dangerous bacteria, arguably the first example of what is now known as immunotherapy. His procedure appeared to shrink some patients’ tumours, but was criticised as unsafe and largely forgotten about. Chemotherapy and radiotherapy became the focus of cancer research and the standard tumour treatment for the rest of the 20th century.

BHI Weekly Newsletter Archives

BHI News Year in Review

Below are BioHealth Innovation News’ most popular articles from 2018:

About BioHealth Innovation

Contact

Connect

Search